Status:
COMPLETED
COVID-19 : Neutralizing Human Monoclonal Antibodies Against SARS-Cov-2
Lead Sponsor:
Hospices Civils de Lyon
Collaborating Sponsors:
Eurobio Scientific
Conditions:
COVID
Eligibility:
All Genders
18+ years
Brief Summary
Rationale : The emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) threatens public health. To date, there are no effective drug option to prevent the infection, nor therapeutics for c...
Eligibility Criteria
Inclusion
- Patient over 18 years old
- Patient who signed the study consent form
- Convalescent patient (at least 12 days after the onset of symptoms), having been sampled at Hospices Civils de Lyon for a suspected infection with SARS-Cov-2, confirmed by PCR.
Exclusion
- Patient treated with rituximab
- Patient treated with immunoglobulins
- Patient over 18 years old, subject to a legal protection measure (guardianship or trusteeship)
- Patient deprived of liberty
- Pregnant or lactating woman
- Patient not affiliated to a social security scheme or beneficiary of a similar scheme.
Key Trial Info
Start Date :
April 29 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 18 2020
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04354766
Start Date
April 29 2020
End Date
May 18 2020
Last Update
June 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital de la Croix-Rousse
Lyon, France